NEW YORK (GenomeWeb) – Biocept reported after the close of the market on Thursday that its first quarter revenues rose dramatically year over year, influenced by a conversion to accrual-based revenue.

For the three months ended March 31, the liquid biopsy firm's total revenues rose to $1.7 million from $221,369 the prior-year quarter. Within Biocept's overall revenue, $897,000 came from commercial testing and another $61,000 was from the firm's development services.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.